

1 **Neuroimmune alterations in autism: a translational analysis focusing on**
2 **the animal model of autism induced by prenatal exposure to valproic acid**

3 Iohanna Deckmann^{1,2,3}, Gustavo Brum Schwingel^{1,2,3}, Mellanie Fontes-
4 Dutra^{1,2,3}, Victorio Bambini-Junior^{1,3,4} and Carmem Gottfried^{1,2,3*}

5 1 Translational Research Group in Autism Spectrum Disorders-GETTEA,
6 Universidade Federal do Rio Grande do Sul -UFRGS, 90035-003 Porto Alegre,
7 RS, Brazil.

8 2 Neuroglial Plasticity Group, Department of Biochemistry, Universidade
9 Federal do Rio Grande do Sul -UFRGS, 90035-003 Porto Alegre, RS, Brazil.

10 3 National Institute of Science and Technology on Neuroimmunomodulation-
11 INCT-NIM.

12 4 School of Pharmacology and Biomedical Sciences, University of Central
13 Lancashire, PR1 2HE, Preston, UK

14

15 *CORRESPONDING AUTHOR:

16 CG (cgottfried@ufrgs.br)

17 Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do
18 Sul, Ramiro Barcelos, 2600 – 21111. CEP: 90035-003. Porto Alegre-RS, Brazil.

19

20

21

22

23

24

1 **ABSTRACT (250 words)**

2 Autism Spectrum Disorder (ASD) is a highly prevalent developmental disorder
3 characterized by deficits in communication and social interaction and in
4 stereotyped or repetitive behaviors. Besides the classical behavioral dyad,
5 several comorbidities are frequently present in patients with ASD, such as
6 anxiety, epilepsy, sleep disturbances and gastrointestinal tract dysfunctions.
7 Although the etiology of ASD remains unclear, there is supporting evidence for
8 the involvement of both genetic and environmental factors. Valproic acid (VPA)
9 is an anticonvulsant and mood stabilizer that, when used during the gestational
10 period, increases the risk of ASD in the offspring. The animal model of autism by
11 prenatal exposure to VPA shows construct and face validity, since several
12 changes seen in subjects with autism are also observed in the VPA animal model.
13 Neuroimmune alterations are common both in autistic individuals and in animal
14 models of autism. In addition, exposure to pathogens during the pregnancy is a
15 known risk factor for ASD, and maternal immune activation can lead to autistic-
16 like features in animals. Thus, immunological alterations in pregnancy could
17 affect the developing embryo, since immune molecules can pass through the
18 placental barrier. Here, we summarize important alterations in inflammatory
19 markers, such cytokines and chemokines in patients with ASD and in the VPA
20 animal model.

21

22 **Keywords** (3–9 key words): ASD, neuroimmune, cytokine, animal model,
23 valproic acid

1 INTRODUCTION

2 Since the first descriptions, in the early 1940's by Leo Kanner and Hans
3 Asperger, new data has been shared to the scientific community about Autism
4 Spectrum Disorder (ASD) [1]. Currently, ASD is diagnosed by changes in two
5 behavioral domains: a) communication and social interaction impairments in
6 multiple contexts, including deficits in social reciprocity, non-verbal
7 communication used for social interaction and in skills to initiate, maintain and
8 understand relationships; and b) Repetitive behaviors, restricted and stereotyped
9 activities [2].

10 There is no clinical marker or quantitative examination in peripheral tissues
11 that can be used for an early diagnosis of this disorder [3]. Even though there are
12 many well accepted surveys for behavioral diagnosis, ASD is a highly complex
13 and heterogeneous disorder, presenting distinct manifestations, in which two
14 individuals hardly share the same set of symptoms [4,5]. The large heterogeneity
15 of the symptoms could potentially be explained by individual differences, for
16 example in the immune system. Alterations in cytokines levels are common in
17 autistic individuals, with a frequent observation of elevated levels of pro
18 inflammatory cytokines [6,7].

19 Genome-wide association studies (GWAS) have already described
20 interesting relations between immune system disruptions and neurological
21 disorders like autism and schizophrenia [8]. Specifically in ASD, an interesting
22 example is the dysregulated genes reported, as IL-1 β and IL-12, both involved in
23 cytokine-cytokine receptor interaction [9]. One study relating ASD and
24 neuroimmune genetic disruption shows an alteration on glutamate receptor

1 metabotropic 5 (GRM5) single nucleotide polymorphisms (SNPs) [10], which is
2 not exactly a neuroimmunological alteration, but this gene is highly expressed in
3 many neuronal regions implicated in ASD, besides acting on synaptic plasticity,
4 modulating innate immunity and microglia activation. When occurs a GRM5-
5 positive allosteric modulation, several negative behaviors described in ASD are
6 rescued, including stereotypies [10]. Taken together, the evidences showing
7 genes interaction and ASD diagnosis demonstrate important genetic contribution
8 in neuroimmunological imbalance in ASD. However, despite the data cited above,
9 no gene was identified as an important actor in triggering this disorder.

10 According to the most recent epidemiological survey conducted in United
11 States, the current incidence of ASD is 1:68 [11]. Although the etiology of ASD
12 remains unknown, it is hypothesized that the onset of this disorder depends on
13 the interplay between genetic and environmental factors. Epidemiological
14 observations suggest that exposure to teratogens - especially in the first trimester
15 of pregnancy - could be closely related to ASD development. An important
16 example is the prenatal exposure to valproic acid (VPA) [12,13].

17 **Valproic acid (VPA) and VPA animal model**

18 The compound VPA is a drug widely used as an anticonvulsant and mood
19 stabilizer in the treatment of epilepsy and bipolar disorder [13,14]. Although VPA
20 is well tolerated and safe in adults, there is evidence of its teratogenicity [14].
21 Clinical studies over the years have shown that intrauterine exposure to VPA is
22 associated with birth defects, cognitive impairments, and increased risk of autism
23 [13]. In recent years, animal studies have investigated the anatomical, behavioral,

1 molecular, immunological and physiological outcomes related to exposure to
2 VPA [13].

3 Epidemiological observations demonstrate a strong correlation between
4 prenatal exposure to VPA and ASD [15–18]. Based on these observations, an
5 animal model for study of autism prenatally induced by VPA was established [19–
6 21]. Behavioral studies show that exposure to VPA in rats and mice leads to
7 several autistic-like behaviors in male offspring, including social behavior deficits,
8 increased repetitive behaviors, and communication deficits similar to those found
9 in ASD subjects [19–23], pointing out the animal model's translationality, as the
10 diagnosis of ASD is given through behavioral evaluation.

11 Since current diagnostic criteria for ASD are exclusively clinical and
12 resulted from behavioral analyses, the study of ASD in humans prior to the onset
13 of symptoms becomes a very challenging task. Animal models provide the
14 opportunity for analyzing the developmental changes that can trigger ASD-like
15 features [24,25]. They provide the possibility to study and manipulate biological
16 pathways for understanding and even preventing or reversing the appearance of
17 the morphological, functional and behavioral alterations found in ASD. In addition,
18 studies with animals can reveal some new important factors involved in the
19 etiology of this disorder.

20 **Histone-deacetylases inhibitors (HDACi) and neuroimmune alterations**

21 Autism and many other psychiatric disorders, like schizophrenia, bipolar
22 disorder and major depression present not only susceptibility to environmental
23 risk factors, but also a high genetic influence [26,27]. In the last years, there is

1 growing evidence indicating that epigenetic alterations may have an important
2 role in several psychiatric disorders.

3 Epigenetic regulation includes long-term changes, as DNA methylation,
4 and short-term changes, as modifications in histone proteins associated with
5 DNA [28]. Histones are small basic proteins that act as spools around which DNA
6 winds, regulating the packaging of DNA and allowing or inhibiting gene
7 expression. When the histone is acetylated by histone acetyltransferases
8 (HATs), this local alteration leads to chromatin decondensation, promoting gene
9 expression by the activation of the transcription machinery. On the other hand,
10 histone deacetylation - mediated by histone deacetylases (HDACs), results in
11 inhibition of transcription promoting a controlled gene expression [28,29].

12 Substantial epigenetic alterations were found in the regulatory regions of
13 many candidate genes for ASD, such as GABAergic genes, GAD67, Reelin,
14 Oxytocin receptor, BDNF, showing that the epigenetic component in ASD has
15 been widely studied [26]. The histone post-translational modifications, as
16 acetylation and methylation, play a key role in the gene expression regulation
17 [30]. These characteristics are crucial for important biological processes like the
18 action of immune system, in which HDACs modulate gene expression of toll-like
19 receptors and interferon signaling pathways [31].

20 The HDAC inhibitors drugs play an important role in immune context.
21 Studies showed an increased transcription of the major histocompatibility
22 complex (MHC) class II, located in the tumor cell surface in mouse and humans
23 [32], indicating an interesting effect on several immune cells. It leads to less
24 viability of T CD4 cells and decreases the production of pro-inflammatory

1 cytokines, making the T CD8 cells increase the secretion of pro-inflammatory
2 cytokines, modulating the activity of natural killer (NK), as well in cells and Treg
3 cells [33].

4 Hence, several drugs used as antidepressants and mood stabilizer are
5 characterized as HDAC inhibitors class. Valproate, a well-known HDAC inhibitor
6 drug, induces important delays in the neuronal maturation [34], already described
7 in ASD [35]. Moreover, VPA prenatal exposure alters the postnatal histone 3 (H3)
8 acetylation levels in cerebellum [36], stimulates glial cell proliferation in the
9 developing rat brain [37] and also induces changes in acetylation levels in
10 astrocytes of hippocampus and cortex in cell culture, more than other
11 antidepressants and mood stabilizer [38]. These unique effects of VPA,
12 especially in comparison to similar HDAC inhibitor drugs, indicate that the VPA
13 molecule might have exclusive properties which are still unclear, although some
14 evidence indicates a possible VPA binding in the catalytic center of HDACs [39].
15 Those epigenetics alterations occur before the well described neuroimmune
16 alterations, and, thus, epigenetics mechanisms may be involved in the immune
17 disturbance [36]. These data highlight the role of the valproic acid and HDAC
18 inhibitors as epigenetic modulators that could be underpinning the immunological
19 alteration, as well as the neurological outcomes, in psychiatric disorders.

20 **The intimate relationship between central nervous system and immune** 21 **system**

22 For a long time, immune and central nervous systems were considered
23 compartments that operate separately and independently. However, recent
24 studies demonstrate an active communication between these two systems,

1 modulating bi-directly each other with neurotransmitters and neuromodulators in
2 periphery. In addition, in a landmark study, lymphatic vessels were discovered in
3 central nervous system, putting in check the current view of the brain as an
4 “immune privileged site” and raising new possibilities for the crosstalk between
5 brain and immune system [40]. Anatomically the central nervous system (CNS)
6 is bathed by the cerebrospinal fluid (CSF) and surrounded by the meninges,
7 which contain lymphatic and blood vessels [41]. The brain parenchyma is
8 separated from the circulating blood by a blood-brain barrier (BBB), which
9 prevents the entry of pathogens, circulating immune cells, and other substances
10 from the blood.

11 The BBB is defined as a semipermeable membrane that separates the
12 circulating blood from the brain and extracellular fluid in the central nervous
13 system [42]. CNS blood vessels interact with different peripheral and brain-
14 resident immune cell populations, as perivascular macrophages and microglial
15 cells, respectively. The BBB is formed by the concerted action of endothelial and
16 glial cells. During development, at embryonic day 10 (E10), initial clues for
17 angiogenesis lead to the early properties of BBB in CNS by activation of the
18 Wnt/b-Catenin canonical pathway [43–45]. There is no consensus about the
19 exact time when the BBB is fully formed [46]. Nevertheless, at E15, pericytes,
20 which have crucial roles in BBB formation and maintenance, begin to interact
21 intimately with endothelial cells (EC) in the capillary walls [47]. In postnatal life,
22 endothelial cells from brain capillaries are covered up by mature pericytes,
23 sharing their basement membrane with endothelial cells [48]. Moreover, the
24 astrocytes project cellular terminations called “end feet” toward the capillaries,
25 providing the outer layer of the BBB. Pericytes and astrocytes also secrete

1 proteins involved in extracellular matrix formation and deposition of the basement
2 membrane [48,49].

3 The presence of this limiting barrier allows the CNS to control and fine tune
4 the flow of a variety of molecules from periphery, regulating its permeability to
5 seek homeostasis. In CNS physiology, there are extensive vessels where
6 monocytes, granulocytes and dendritic cells circulate [50]. In addition, the brain
7 parenchyma is populated with microglia, resident-cells from the immune lineage
8 that play crucial roles in brain surveillance and response against multiple types
9 of damage. Studies with rodents showed that, during neurodevelopment, specific
10 monocytes emerge at E7 and infiltrate the CNS at E9.5 as pre-macrophages,
11 expressing the chemotactic factor CX3C chemokine-receptor 1 (CX3CR1) [50].
12 The presence of cytokines as interleukin-1 beta (IL-1 β) and tumor growth factor
13 beta (TGF- β) allows the differentiation of pre-macrophages in early microglia at
14 E14.5, which then generate mature microglia at P14. In fact, TGF- β seems to be
15 crucial for microglial specification in CNS [51,52].

16 Microglial cells are capable to interact with almost all cell types in the CNS
17 modulating cell maturation during development and promoting tissue repair and
18 homeostasis. Moreover, in postnatal life, microglia play crucial roles in sensing
19 perturbations in encephalic environment, actively responding to even minor
20 pathological changes in CNS [53,54] by altering their shape and gene expression
21 profile. The term “microglial activation” has been considered as a shift from a
22 “resting” stage to an “activated” state when disturbance of tissue homeostasis is
23 detected or upon experimental stimulation. However, this term implies the
24 understanding of an “inactivated” phenotype when brain tissue is not facing any

1 changes in homeostasis. In fact, microglial cells are never inactive, showing
2 highly dynamic surveillance functions in CNS [50,55,56]. Many authors are
3 suggesting to rename this surveillance state of microglial cells to “surveying
4 microglia”, instead of “resting microglia” [50]. These cells can shift from their
5 “surveying” or “resting” state to “activated” or “alerted” state when facing changes
6 in CNS homeostasis, as infections recognized by toll-like receptors [57], cell
7 damage or trauma. Recent studies have demonstrated that the
8 lipopolysaccharide (LPS) exposure downregulates the transcriptional factor Sal-
9 like protein 1 (SALL1) and promotes several alterations in microglial identity, with
10 a concomitant upregulation of genes associated to other resident macrophages,
11 indicating that SALL1 might be important for maintenance of microglial identity in
12 response to immune challenge [50,58]. Once activated, microglial cells can
13 commit to different phenotypes called “reactive”, having a large functional and
14 molecular diversity. These changes in microglia profile are correlated with the
15 type of challenge faced by the CNS. They can shift to a pro-inflammatory state
16 also called “M1 phenotype” [59] presenting highly phagocytic and neurotoxic
17 activities and releasing pro-inflammatory chemokines and cytokines in response
18 to an immune challenge, such as a microorganism invasion [60] or the presence
19 of pro inflammatory signals [61–63]. Once the immune stimulator is controlled,
20 microglial cells are able to shift to a more neuroprotective profile called “M2
21 phenotype” which involves anti-inflammatory responses [59,64]. Nonetheless,
22 the activated pro-inflammatory profile can progress in pathological conditions.
23 Although the immune challenge and the brain environment are responsible for
24 the early microglial responses, signals from CNS resident and infiltrating immune
25 cells can shape reactive profiles of microglial cells and play important roles in

1 many brain diseases [65–69]. All these stimuli could direct microglia’s fate to
2 alternative states, including microglial cell death, but there’s still scarce
3 information about the course of microglial activation, their reversibility to the
4 surveying state [70] or the preservation of molecular memory of previous stimuli.
5 Moreover, cells that infiltrate from the blood and differentiated into microglia could
6 also return to the periphery [65,71].

7 There is a low basal entry of immune cells from blood periphery into the
8 CNS in normal conditions. Studies have shown that, although microglial cells play
9 major roles in brain surveillance, the perivascular macrophages represent a
10 crucial immune regulator and sensor of perturbations in CNS and periphery.
11 These cells are derived from bone marrow and are intimately associated with the
12 bloodstream since they reside between endothelial cells and astrocyte’s end feet
13 [72–74]. This privileged location of perivascular macrophages allow them to
14 simultaneously monitor the blood and the brain interstitial fluid, providing a fine
15 control of brain homeostasis and BBB integrity [72,75]. Although macrophages
16 display different locations, they can perform specific roles in these
17 microenvironments. In addition to perivascular space, macrophages can be
18 located within choroid plexus and meningeal space. In choroid plexus, which is
19 considered the major site of CNS immune surveillance, there are tissue-resident
20 macrophages called epiplexus cells disposed alongside the fourth ventricle with
21 dendritic cells (DC), monocytes and mast cells [76,77]. Referred by many authors
22 as the “immune regulatory gate”, the choroid plexus is capable to induce specific
23 immune responses and allows cell migration between blood and CSF [78,79].
24 The meningeal macrophages are positioned in the subdural meninges and act as
25 sentinel cells for damage and infection in brain tissue, surveying the

1 cerebrospinal fluid (CSF) and the extracellular lumen of meningeal blood vessels
2 [80,81]. Thus, macrophages play critical roles in CNS surveillance, homeostasis
3 and disease. Nonetheless, there is a variety of other immune cell types in the
4 brain environment. In physiological condition, studies have observed the
5 presence of monocytes in meningeal spaces, although more evidence is still
6 needed [82]. Granulocytes (neutrophils, mast cells, eosinophils, and basophils)
7 can be found in meningeal spaces with mast cells also present in brain
8 parenchyma [72,83]. These cells are highly phagocytic and play important roles
9 in response to brain infections and tissue damage [72,84,85]. Dendritic cells (DC),
10 the main antigen-presenting cells in periphery, can also be found in CNS. They
11 are located in the choroid plexus, meningeal space, and are specially abundant
12 in lymphatic vessels in meninges [86–88]. The presence around these vessels
13 suggests important roles for DC in inflammatory diseases and brain infections
14 [40].

15 During inflammatory condition, there is extensive infiltration of immune
16 cells in the CNS. The barriers that regulate cellular entry are the blood-brain
17 barrier (BBB) within the CNS parenchyma, and the blood-cerebrospinal fluid
18 (blood-CSF) barrier within the choroid plexus” [89]. When brain homeostasis is
19 compromised, immune cells can infiltrate from the periphery to the brain
20 parenchyma due to the elevation in BBB permeability. This is generally observed
21 and investigated in the context of a pathological CNS inflammatory response [90–
22 92]. Under pathological conditions, microglia activation can lead to BBB
23 disruption, allowing a substantial cellular infiltrate and amplifying the inflammatory
24 response [93,94]. One of the key mediators in these processes is the release of
25 cytokines and chemokines by periphery and brain-resident immune cells. This

1 novel view of the immune system as an active player in brain function is modifying
2 our current view of neuropsychiatric disorders. Immune alterations are now seen
3 as central for the pathophysiology of many brain diseases and further
4 understanding of this neuroimmune axis can result in new therapies and
5 diagnostic tools.

6 **Neuroimmune alterations in ASD: from patients to the VPA animal model**

7 In the last decade, the immune system has caught the attention of
8 neuroscientists for the interplay between neurons and immune mediators, not
9 only in disease, but also in the homeostasis of the brain. In the past, the central
10 nervous system was called “an immune-privileged region”, once the blood brain
11 barrier controls the cross talking between brain and the periphery. However,
12 recent findings demonstrated that this privilege is not related to the absence of
13 immune modulation in brain activity and homeostasis, but a time-dependent
14 specific modulation in many regions during brain development [95]. Immune cells
15 and immune molecules, such as cytokines and chemokines, can modulate
16 cognitive, emotional and behavioral processes, triggering different responses in
17 neuronal and glial cells [96]. Cytokines are small signaling-molecules acting as
18 mediators of communication between immune cells. Their roles include
19 stimulation and regulation of cell development, maturation and response against
20 immune challenges [97,98]. Chemokines can be characterized as a vast group
21 of 8-10 kDa molecules from the super family of cytokines that induce chemotaxis
22 of immune cells. Once bound in their receptor, the complex chemokine-receptor
23 can activate signaling cascades that induce immune cell trafficking to the target
24 area. Also, this complex plays important roles as molecular signal in crosstalk

1 among neuronal and glial cells and immune resident cells in nervous system, as
2 microglia [99,100]. Since chemokines are capable to target different types of
3 receptor, they can modulate different cell processes, including cell adhesion,
4 proliferation, phagocytosis, apoptosis, angiogenesis, cytokine secretion and T
5 cell activation [101].

6 Lymphocytes are cells capable of recognizing any foreign antigens
7 displayed by antigen-presenting cells, constituting the main cells of adaptive
8 immunity [102]. Lymphocytes respond by proliferating and differentiating in
9 effector cells, whose function is the elimination of the pathogen and creation of
10 an immunological memory [103]. When naïve CD4+ T cells encounter specific
11 antigens, they can differentiate into a range of effector subgroups. Several
12 transcription factors are individually required for T-cell differentiation, generating
13 a specific lineage that express characteristic cytokines. That is, once specific
14 transcription factors are activated, they promote differentiation of naïve T cells,
15 which differentiate into specific immunological responses: Th1, Th2 and Th17. In
16 the presence of IFN- γ and IL-12, Signal transducer and activator of transcription
17 (STAT) 1 and STAT4 signal for the expression of the transcription factor T box
18 expressed in T cells (T-bet) and promotes response Th1. On the other hand, Th2
19 cell commitment occurs when IL-4 and STAT6 increase expression of GATA-
20 binding protein (GATA3) transcription factor. The presence of TGF- β associated
21 with IL-6 signaling via STAT3 generating the expression of retinoid-related
22 orphan receptor (ROR γ t) transcription factor, results in the differentiation of Th17
23 cells. Also, TGF- β , with IL-2 signaling via STAT5 is known to generate, at least
24 in vitro, inducible Treg cells, which express Foxp3 transcription factor (See Figure
25 1) [104].

1 The modulation of cytokine levels can alter significantly the brain
2 physiology and behavior. Recent studies highlight a link between immune
3 dysfunction and behavioral impairments [105]. For example, the relation between
4 IL-6 and several altered behaviors has already been established in the literature
5 [106–108]. Signs of neuroinflammation and altered inflammatory response are
6 seen in ASD subjects throughout life [109]. Therefore, some authors hypothesize
7 that the neuroimmune disturbances could be causal for ASD [110]. Below, we will
8 detail the main neuroimmunological findings (summarized in Tables 1 and 2) in
9 ASD subjects and in VPA animal model of autism:

10 *IL-1 β*

11 IL-1 β is a cytokine produced by fibroblasts, monocytes, tissue
12 macrophages, dendritic cells (DCs), B lymphocytes, epithelial cells, and natural
13 killer (NK) cells [111] that promotes inflammation by indirectly stimulating
14 lymphocyte function and activating macrophages [112,113]. IL-1 β has the ability
15 to increase the expression of adhesion molecules such as VCAM-1 and ICAM-
16 1, supporting the infiltration of inflammatory cells from the circulation into the
17 tissue and resulting in chronic IL-1-induced inflammation [112,113]. IL-1 β
18 stimulates expression of inflammatory mediators and induces T-helper type 17
19 (Th17) response. Furthermore it can also play important roles as a mediator of
20 the anti-inflammatory response [112,113].

21 Both elevation and reduction in IL-1 β levels have already been reported in
22 ASD subjects. Increased levels of IL-1 β were found in plasma [114,115], serum
23 [116,117], and peripheral blood mononuclear cells (PBMCs) [118–120] whereas
24 decreased levels were described in neonatal dried blood samples (n-DBSS)

1 [121]. In VPA animal model, IL-1 β was increased in hippocampus [122,123], in
2 LPS-exposed hippocampus [109] and in whole brain homogenate [124].
3 Increased levels of this cytokine are associated with increased stereotypy [120],
4 one of the main characteristics of ASD.

5 *IL-2*

6 Interleukin-2 has an important role in controlling the survival of immature
7 and mature T cells [125] and is mainly secreted by CD8+ and CD4+ T cells after
8 recognition of the antigen and co-stimulators [111]. IL-2 is the most important
9 cytokine for promoting the clonal expansion of antigen-activated T cells [126].
10 The only report in ASD is a reduction of IL-2 levels in neonatal dried blood
11 samples (n-DBSS) [121].

12 *IL-4*

13 IL-4 is the main cytokine of Th2 response and is primarily produced by T
14 cells and mast cells. IL-4 promotes proliferation of B cells and cytotoxic T cells
15 and stimulates IgG and IgE production [97], besides stimulating leukocytes
16 recruitment and promoting the expression of adhesion molecules [127].
17 Increased levels of this cytokine were associated with greater impairments in non-
18 verbal communication [120]. In ASD subjects, reduced level of IL-4 in n-DBSS
19 [121] and elevated levels in amniotic fluid [128] have been reported.

20 *IL-5*

21 IL-5 is a cytokine produced by T cells that acts as an activator of
22 eosinophils [129]. IL-5 promotes eosinophil proliferation and maturation,

1 stimulating IgA and IgM production [97]. In ASD patients, a decrease in IL-5 in n-
2 DBSS [121] and an increase in plasma samples [115] were described.

3 *IL-6*

4 The main source of IL-6 are T-helper cells, macrophages and fibroblasts.
5 IL-6 targets activated B-cells and plasma cells, promoting differentiation into
6 plasma cells and IgG production [97]. IL-6 is also involved in induction of Th17
7 response and has a dual profile pro- and anti-inflammatory [112,113]. Studies
8 have demonstrated essential involvement of IL-6 in triggering core symptoms
9 related to pro-inflammatory response in autistic model of maternal immune
10 activation (MIA) [130].

11 Increased levels of IL-6 are associated with increased stereotypy in ASD
12 [120], impaired cognitive abilities, abnormal anxiety and decreased social
13 interactions [107]. Here, we review the main findings about IL-6 levels in ASD: IL-
14 6 is elevated in brain tissue (cerebellum, frontal cortex and anterior cingulated
15 gyrus) [7,131,132], and in serum and PBMC [116–120], while it is reduced in
16 plasma and n-DBSS [114,121]. In the VPA animal model of autism, higher levels
17 of IL-6 were reported in hippocampus [123], hippocampus and spleen after LPS
18 challenge [109] and whole brain homogenate [124].

19 *IL-8*

20 Interleukin-8 is a chemoattractant cytokine produced mainly by
21 macrophages that specifically targets neutrophils, promoting their activation
22 [133]. So, its major functions result from its chemotactic and pro-inflammatory
23 activities [97]. Elevated levels of this cytokine were associated with increased

1 hyperactivity, stereotypy, and lethargy [120]. Higher levels of IL-8 was described
2 in frontal cortex [132], plasma [115], cerebrospinal fluid (CSF) [134], PBMCs [120]
3 and n-DBSS [121] of ASD subjects.

4 *IL-10*

5 This cytokine can be produced by several cellular types including DCs,
6 macrophages, mast cells, NK cells, eosinophils, neutrophils and B cells [135],
7 and is able to regulate growth and/or differentiation of B cells, NK cells, cytotoxic
8 and helper T cells, mast cells, granulocytes, dendritic cells, keratinocytes, and
9 endothelial cells, exerting a primarily anti-inflammatory activity [97,135]. IL-10 is
10 important to fine tune the immune response against invading pathogens,
11 maintaining the homeostatic state [135]. In ASD patients, increased levels to IL-
12 10 were found in anterior cingulated gyrus and amniotic fluid [128,134], while IL-
13 10 levels is decreased in PBMCs [96].

14 *IL-12*

15 IL-12 is produced by T cell and acts in naïve T-cells and NK cells,
16 activating them [97], and inducing IFN γ production, which is critical for the
17 induction of Th1 cells [136]. Plasma, PBMCs and serum of ASD subjects show
18 higher levels of IL-12 [115,117,120] whereas n-DBSS show lower IL-12 levels
19 [121]. Increased IL-12 levels were associated with increased stereotypy and
20 lethargy in ASD patients [120].

21 *IL-13*

1 Similarly to IL-4, IL-13 is involved in type-2 immunity and is produced by
2 T-cells. However, basophils, eosinophils and NK cells can also produce IL-13
3 [137]. The only report in autistic patients shows increased plasma levels of IL-13
4 [115].

5 *IL-17*

6 Interleukin-17 has an important role in immunity against intra and
7 extracellular pathogens [138]. IL-17-producing cells including natural killer T cells
8 and innate lymphoid cells play crucial roles in inflammation-associated diseases,
9 such as infection, autoimmunity and tumors [139]. Also was described the effector
10 role of IL-17a in onset of offspring behavioral abnormalities of mothers MIA-
11 induced, showing the important crosstalk between the neuroinflammatory state
12 and behavioral manifestations [140]. Increase levels of IL-17 have been reported
13 in plasma and serum [115,141] of patients with ASD.

14 *IL-23*

15 Considered a pro-inflammatory cytokine essential for the differentiation of
16 Th17 lymphocytes [142], IL-23 is produced by macrophages, dendritic cells,
17 keratinocytes and other antigen-presenting cells after recognition of
18 microorganisms [143]. IL-23 is critically involved in autoimmune diseases
19 responses [144]. In autistic patients, elevated IL-23 levels in serum samples were
20 reported [117].

21 *TNF- α*

1 The tumor necrosis factor alpha (TNF α) is an endotoxin-induced serum
2 factor promoting phagocyte cell activation [97], whose main targets and
3 producers are macrophages. TNF α is in higher levels both in patients (frontal
4 cortex [132], PBMC [96,118,119,145], serum [117] and amniotic fluid [128]) and
5 in the VPA animal model of autism (hippocampus and spleen responding to LPS
6 [109] and whole brain tissue [124]).

7 *IFN- γ*

8 Interferon- γ (IFN- γ) plays an important role in host defense against
9 intracellular pathogens. It is produced by NK T cells, CD8+ T cells, and T-helper
10 1 (Th1) CD4+ T cells and its functions include supporting Th1 differentiation [146],
11 and macrophage activation and increasing neutrophil and monocyte function [97].
12 Patients with ASD have increased levels of IFN- γ in frontal cortex [132], plasma
13 [147], CSF [134] and PBMC [96] and reduced levels in n-DBSS [121].

14 *TGF β 1*

15 TGF- β is primarily secreted by T cells and B cells, and acts in activated T
16 and B cells. The major function of this cytokine is to inhibit hematopoiesis and T
17 and B cell proliferation [97]. Higher levels to TGF β 1 were reported in anterior
18 cingulated gyrus and CSF [134] of ASD subjects.

19 *MCP-1*

20 Monocyte Chemoattractant Protein-1 (MCP-1) or C-C chemokine ligand 2
21 (CCL2) signals to cells that contain the specific CCR2 receptor, stimulating their
22 migration to sites where CCL2 is produced and facilitating the amplification of

1 neuroinflammation [148]. Higher levels of MCP-1 were observed in plasma [149],
2 CSF [134] and amniotic fluid [128] of autistic subjects. Increased levels in plasma
3 were associated with greater impairments in visual reception, fine motor skills
4 and expressive language [149].

5 *GM-CSF*

6 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is produced
7 by T cells, macrophages and fibroblasts and targets stem cells. Its major function
8 is to stimulate production of granulocyte, monocyte and eosinophils [97].
9 Diminished levels of GM-CSF were described in n-DBSS of ASD pediatric
10 subjects [121].

11 *G-CSF*

12 The main source of granulocyte colony-stimulating factor (G-CSF) are
13 fibroblasts and endothelial cells and its targets are stem cells in the bone marrow.
14 G-CSF has a hematopoietic function and stimulates granulocyte production [97].
15 Higher levels of this cytokine were described in plasma of autistic patients [114].

16 *EGF*

17 Epidermal growth factor (EGF) is a small chemoattractant peptide
18 produced by activated T cells that is involved with wound healing by attracting
19 fibroblasts and epithelial cells [114]. Higher levels of this chemokine were
20 reported in plasma samples from autistic patients [114].

21 *RANTES*

1 Regulated on Activation, Normal T-cell Expressed and Secreted
2 (RANTES) chemokine or CCL5 is involved in immune cell transport to the
3 inflammation site, promoting polarization towards an Th1 response [150]. Higher
4 levels were associated with increased severity of lethargy, stereotypy and
5 hyperactivity [149] in ASD patients.

6 *Eotaxin*

7 The CC chemokine eotaxin/CCL11 is known to bind to the receptor CCR3
8 on eosinophils and Th2-type lymphocytes [151]. Increased levels of Eotaxin were
9 associated with increased severity of lethargy, stereotypy and hyperactivity in
10 ASD subjects [149].

11 **Final considerations**

12 Autistic Spectrum Disorder has a high prevalence and a growing incidence
13 over the last few years. This has driven investments in public health and
14 mobilized researchers and health professionals worldwide. There has been a
15 significant progress in ASD research since the disorder was first described, but
16 to date, its etiology remains unclear. An interesting hypothesis is that
17 dysregulation of neuroimmune communication is involved in the onset of ASD. In
18 this review, we summarized the main neuroimmune alterations found both in ASD
19 subjects and in the VPA animal model of autism. Noticeably, several changes in
20 the VPA model reflect the alterations found in patients with ASD (Figure 2).
21 Animal models that present face and construct validity, such as the VPA model,
22 can be an effective tool for the investigation of pathways and tissue alterations
23 involved with the pathogenesis of ASD.

1 **Acknowledgments**

2 This work was supported by development agencies: Conselho Nacional
3 de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de
4 Aperfeiçoamento de Pessoal de Nível Superior (Capes) e Instituto Nacional de
5 Ciência e Tecnologia em NeuroImunoModulação (INCT-NIM). The authors have
6 no conflicts of interest.

7 **References**

- 8 1 Leo Kanner: Autistic disturbance of affective contact. *Pathology* 1943
9 [cited 2018 Jan 27];2:217–250.
- 10 2 APA - American Psychiatric Association: DSM-5 Diagnostic Classification;
11 in : *Diagnostic and Statistical Manual of Mental Disorders*. American
12 Psychiatric Association, 2013. DOI:
13 10.1176/appi.books.9780890425596.x00DiagnosticClassification
- 14 3 Huerta M, Lord C: Diagnostic Evaluation of Autism Spectrum Disorders.
15 *Pediatr Clin North Am* 2012;103–111.
- 16 4 Gadia CA, Tuchman R, Rotta NT: Autismo e doenças invasivas de
17 desenvolvimento. *J Pediatr* 2004 [cited 2018 Jan 27];S83–S94.
- 18 5 Rapin I, Tuchman RF: Autism: Definition, Neurobiology, Screening,
19 Diagnosis. *Pediatr Clin North Am* 2008;55:1129–1146.
- 20 6 Tonhajzerova I, Ondrejka I, Mestanik M, Mikolka P, Hrtanek I,
21 Mestanikova A, et al.: Inflammatory Activity in Autism Spectrum Disorder;
22 in : *Advances in experimental medicine and biology*. 2015, pp 93–98.
- 23 7 Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA:

1 Neuroglial activation and neuroinflammation in the brain of patients with
2 autism. *Ann Neurol* 2005;57:67–81.

3 8 Autism Spectrum Disorders Working Group of The Psychiatric Genomics
4 Consortium TASDWG of TPG: Meta-analysis of GWAS of over 16,000
5 individuals with autism spectrum disorder highlights a novel locus at
6 10q24.32 and a significant overlap with schizophrenia. *Mol Autism*
7 2017;8:21.

8 9 Lintas C, Sacco R, Persico AM: Genome-wide expression studies in
9 Autism spectrum disorder, Rett syndrome, and Down syndrome.
10 *Neurobiol Dis* 2012;45:57–68.

11 10 Skafidas E, Testa R, Zantomio D, Chana G, Everall IP, Pantelis C:
12 Predicting the diagnosis of autism spectrum disorder using gene pathway
13 analysis. *Mol Psychiatry* 2014;19:504–510.

14 11 Christensen DL, Baio J, Braun KVN, Bilder D, Charles J, Constantino JN,
15 et al.: Prevalence and Characteristics of Autism Spectrum Disorder
16 Among Children Aged 8 Years — Autism and Developmental Disabilities
17 Monitoring Network, 11 Sites, United States, 2012. *MMWR Surveill Summ*
18 2016;65:1–23.

19 12 Smith V, Brown N: Prenatal valproate exposure and risk of autism
20 spectrum disorders and childhood autism. *Arch Dis Child Educ Pract Ed*
21 2014;99:198.

22 13 Roullet FI, Lai JKY, Foster JA: In utero exposure to valproic acid and
23 autism - A current review of clinical and animal studies. *Neurotoxicol*
24 *Teratol* 2013;36:47–56.

- 1 14 Ranger P, Ellenbroek BA: Perinatal Influences of Valproate on Brain and
2 Behaviour: An Animal Model for Autism; in : Current topics in behavioral
3 neurosciences. 2015, pp 363–386.
- 4 15 Christianson AL, Chester N, Kromberg JGR: Fetal Valproate Syndrome:
5 Clinical and Neuro-developmental Features in Two Sibling Pairs. *Dev*
6 *Med Child Neurol* 1994;36:361–369.
- 7 16 Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, et
8 al.: A clinical study of 57 children with fetal anticonvulsant syndromes. *J*
9 *Med Genet* 2000 [cited 2018 Jan 29];37:489–497.
- 10 17 Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH: Fetal
11 valproate syndrome and autism: additional evidence of an association.
12 *Dev Med Child Neurol* 2001;43:202–206.
- 13 18 Williams PG, Hersh JH: A male with fetal valproate syndrome and autism.
14 *Dev Med Child Neurol* 1997;39:632–634.
- 15 19 Bambini-Junior V, Rodrigues L, Behr GA, Moreira JCF, Riesgo R,
16 Gottfried C: Animal model of autism induced by prenatal exposure to
17 valproate: behavioral changes and liver parameters. *Brain Res*
18 2011;1408:8–16.
- 19 20 Schneider T, Przewłocki R: Behavioral Alterations in Rats Prenatally
20 Exposed to Valproic Acid: Animal Model of Autism.
21 *Neuropsychopharmacology* 2005;30:80–89.
- 22 21 Schneider T, Roman A, Basta-Kaim A, Kubera M, Budziszewska B,
23 Schneider K, et al.: Gender-specific behavioral and immunological
24 alterations in an animal model of autism induced by prenatal exposure to

- 1 valproic acid. *Psychoneuroendocrinology* 2008;33:728–740.
- 2 22 Rouillet FI, Wollaston L, Decatanzaro D, Foster JA: Behavioral and
3 molecular changes in the mouse in response to prenatal exposure to the
4 anti-epileptic drug valproic acid. *Neuroscience* 2010;170:514–22.
- 5 23 Baronio D, Castro K, Gonchoroski T, de Melo GM, Nunes GDF, Bambini-
6 Junior V, et al.: Effects of an H3R Antagonist on the Animal Model of
7 Autism Induced by Prenatal Exposure to Valproic Acid. *PLoS One*
8 2015;10:e0116363.
- 9 24 Favre MR, Barkat TR, Lamendola D, Khazen G, Markram H, Markram K:
10 General developmental health in the VPA-rat model of autism. *Front*
11 *Behav Neurosci* 2013;7:88.
- 12 25 Kataoka S, Takuma K, Hara Y, Maeda Y, Ago Y, Matsuda T: Autism-like
13 behaviours with transient histone hyperacetylation in mice treated
14 prenatally with valproic acid. *Int J Neuropsychopharmacol* 2013;16:91–
15 103.
- 16 26 Zhubi A, Cook EH, Guidotti A, Grayson DR: Epigenetic mechanisms in
17 autism spectrum disorder. ed 1 Elsevier Inc., 2014. DOI: 10.1016/B978-0-
18 12-801311-3.00006-8
- 19 27 Uher R: Gene-environment interactions in severe mental illness. *Front*
20 *psychiatry* 2014;5:48.
- 21 28 Misztak P, Pańczyszyn-Trzewik P, Sowa-Kućma M: Histone deacetylases
22 (HDACs) as therapeutic target for depressive disorders. *Pharmacol*
23 *Reports* 2018;70:398–408.
- 24 29 Koprinarova M, Schnekenburger M, Diederich M: Role of Histone

1 Acetylation in Cell Cycle Regulation. *Curr Top Med Chem* 2015;16:732–
2 744.

3 30 Nadal S, Raj R, Mohammed S, Davis BG: Synthetic post-translational
4 modification of histones. *Curr Opin Chem Biol* 2018;45:35–47.

5 31 Hu Y, Suliman BA: Roles of HDACs in the Responses of Innate Immune
6 Cells and as Targets in Inflammatory Diseases. *Adv Exp Med Biol*
7 2017;1024:91–110.

8 32 Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C,
9 et al.: Activation of MHC class I, II, and CD40 gene expression by histone
10 deacetylase inhibitors. *J Immunol* 2000 [cited 2018 Mar 18];165:7017–24.

11 33 Kroesen M, Gielen PR, Brok IC, Armandari I, Hoogerbrugge PM, Adema
12 GJ: HDAC inhibitors and immunotherapy; a double edged sword?
13 *Oncotarget* 2014;5:6558–6572.

14 34 Kawanai T, Ago Y, Watanabe R, Inoue A, Taruta A, Onaka Y, et al.:
15 Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene
16 Expression of Autism-Related Molecules and Delays Neuronal
17 Maturation. *Neurochem Res* 2016;41:2574–2584.

18 35 Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria K, et al.:
19 Altered proliferation and networks in neural cells derived from idiopathic
20 autistic individuals. *Mol Psychiatry* 2017;22:820–835.

21 36 Kazlauskas N, Campolongo M, Lucchina L, Zappala C, Depino AM:
22 Postnatal behavioral and inflammatory alterations in female pups
23 prenatally exposed to valproic acid. *Psychoneuroendocrinology*
24 2016;72:11–21.

- 1 37 Lee HJ, Dreyfus C, DiCicco-Bloom E: Valproic acid stimulates
2 proliferation of glial precursors during cortical gliogenesis in developing
3 rat. *Dev Neurobiol* 2016;76:780–798.
- 4 38 Perisic T, Zimmermann N, Kirmeier T, Asmus M, Tuorto F, Uhr M, et al.:
5 Valproate and amitriptyline exert common and divergent influences on
6 global and gene promoter-specific chromatin modifications in rat primary
7 astrocytes. *Neuropsychopharmacology* 2010;35:792–805.
- 8 39 Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al.:
9 Valproic acid defines a novel class of HDAC inhibitors inducing
10 differentiation of transformed cells. *EMBO J* 2001;20:6969–78.
- 11 40 Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et
12 al.: Structural and functional features of central nervous system lymphatic
13 vessels. *Nature* 2015;523:337–41.
- 14 41 Louveau A, Harris TH, Kipnis J: Revisiting the Mechanisms of CNS
15 Immune Privilege. *Trends Immunol* 2015;36:569–577.
- 16 42 Daneman R, Prat A: The blood-brain barrier. *Cold Spring Harb Perspect
17 Biol* 2015;7:a020412.
- 18 43 Wang Y, Rattner A, Zhou Y, Williams J, Smallwood PM, Nathans J:
19 Norrin/Frizzled4 Signaling in Retinal Vascular Development and Blood
20 Brain Barrier Plasticity. *Cell* 2012;151:1332–1344.
- 21 44 Zhou Y, Nathans J: Gpr124 Controls CNS Angiogenesis and Blood-Brain
22 Barrier Integrity by Promoting Ligand-Specific Canonical Wnt Signaling.
23 *Dev Cell* 2014;31:248–256.
- 24 45 Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, et

1 al.: Canonical WNT signaling components in vascular development and
2 barrier formation. *J Clin Invest* 2014;124:3825–3846.

3 46 Hagan N, Ben-Zvi A: The molecular, cellular, and morphological
4 components of blood-brain barrier development during embryogenesis.
5 *Semin Cell Dev Biol* 2015;38:7–15.

6 47 Zhao Z, Nelson AR, Betsholtz C, Zlokovic B V: Establishment and
7 Dysfunction of the Blood-Brain Barrier. *Cell* 2015;163:1064–1078.

8 48 Daneman R, Zhou L, Kebede AA, Barres BA: Pericytes are required for
9 blood–brain barrier integrity during embryogenesis. *Nature*
10 2010;468:562–566.

11 49 Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al.:
12 Pericytes Control Key Neurovascular Functions and Neuronal Phenotype
13 in the Adult Brain and during Brain Aging. *Neuron* 2010;68:409–427.

14 50 Li Q, Barres BA: Microglia and macrophages in brain homeostasis and
15 disease. *Nat Rev Immunol* 2017; DOI: 10.1038/nri.2017.125

16 51 Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely
17 G, et al.: Identification of a unique TGF- β -dependent molecular and
18 functional signature in microglia. *Nat Neurosci* 2014;17:131–143.

19 52 Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres
20 BA: Diverse Requirements for Microglial Survival, Specification, and
21 Function Revealed by Defined-Medium Cultures. *Neuron* 2017;94:759–
22 773.e8.

23 53 Kreutzberg GW: Microglia: a sensor for pathological events in the CNS.
24 *Trends Neurosci* 1996 [cited 2018 Mar 23];19:312–8.

- 1 54 Raivich G, Banati R: Brain microglia and blood-derived macrophages:
2 molecular profiles and functional roles in multiple sclerosis and animal
3 models of autoimmune demyelinating disease. *Brain Res Rev*
4 2004;46:261–281.
- 5 55 Nimmerjahn A, Kirchhoff F, Helmchen F: Resting Microglial Cells Are
6 Highly Dynamic Surveillants of Brain Parenchyma in Vivo. *Science* (80-)
7 2005;308:1314–1318.
- 8 56 Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J: Resting
9 Microglia Directly Monitor the Functional State of Synapses In Vivo and
10 Determine the Fate of Ischemic Terminals. *J Neurosci* 2009;29:3974–
11 3980.
- 12 57 Olson JK, Miller SD: Microglia initiate central nervous system innate and
13 adaptive immune responses through multiple TLRs. *J Immunol* 2004
14 [cited 2018 Mar 23];173:3916–24.
- 15 58 Buttgereit A, Lelios I, Yu X, Vrohling M, Krakoski NR, Gautier EL, et al.:
16 Sall1 is a transcriptional regulator defining microglia identity and function.
17 *Nat Immunol* 2016;17:1397–1406.
- 18 59 Parisi C, Napoli G, Pelegrin P, Volonté C: M1 and M2 Functional
19 Imprinting of Primary Microglia: Role of P2X7 Activation and miR-125b.
20 *Mediators Inflamm* 2016;2016:2989548.
- 21 60 Hanisch U-K, Prinz M, Angstwurm K, Hausler KG, Kann O, Kettenmann
22 H, et al.: The protein tyrosine kinase inhibitor AG126 prevents the massive
23 microglial cytokine induction by pneumococcal cell walls. *Eur J Immunol*
24 2001 [cited 2018 Mar 23];31:2104–2115.

- 1 61 Häusler KG, Prinz M, Nolte C, Weber JR, Schumann RR, Kettenmann H,
2 et al.: Interferon-gamma differentially modulates the release of cytokines
3 and chemokines in lipopolysaccharide- and pneumococcal cell wall-
4 stimulated mouse microglia and macrophages. *Eur J Neurosci* 2002 [cited
5 2018 Mar 23];16:2113–22.
- 6 62 Škuljec J, Sun H, Pul R, Bénardais K, Ragancokova D, Moharregg-
7 Khiabani D, et al.: CCL5 induces a pro-inflammatory profile in microglia in
8 vitro. *Cell Immunol* 2011;270:164–171.
- 9 63 Zarruk JG, Greenhalgh AD, David S: Microglia and macrophages differ in
10 their inflammatory profile after permanent brain ischemia. *Exp Neurol*
11 2018;301:120–132.
- 12 64 Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, et al.: Microglial and
13 macrophage polarization—new prospects for brain repair. *Nat Rev Neurol*
14 2015;11:56–64.
- 15 65 Hanisch U-K, Kettenmann H: Microglia: active sensor and versatile
16 effector cells in the normal and pathologic brain. *Nat Neurosci*
17 2007;10:1387–1394.
- 18 66 Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, et
19 al.: Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial
20 Activation States and Aspects of Alzheimer’s Disease Not Evident in
21 Mouse Models. *Cell Rep* 2018;22:832–847.
- 22 67 Koyama R, Ikegaya Y: Microglia in the pathogenesis of autism spectrum
23 disorders. *Neurosci Res* 2015;100:1–5.
- 24 68 Hansen D V., Hanson JE, Sheng M: Microglia in Alzheimer’s disease. *J*

1 Cell Biol 2018;217:459–472.

2 69 Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF,
3 Lassmann H, et al.: Inflammatory Cortical Demyelination in Early Multiple
4 Sclerosis. *N Engl J Med* 2011;365:2188–2197.

5 70 Antonietta Ajmone-Cat M, Mancini M, De Simone R, Cilli P, Minghetti L:
6 Microglial polarization and plasticity: Evidence from organotypic
7 hippocampal slice cultures. *Glia* 2013;61:1698–1711.

8 71 Serhan CN, Savill J: Resolution of inflammation: the beginning programs
9 the end. *Nat Immunol* 2005;6:1191–1197.

10 72 Herz J, Filiano AJ, Smith A, Yogev N, Kipnis J: Myeloid Cells in the
11 Central Nervous System. *Immun Rev* 2017; DOI:
12 10.1016/j.immuni.2017.06.007

13 73 Serrats J, Schiltz JC, García-Bueno B, van Rooijen N, Reyes TM,
14 Sawchenko PE: Dual Roles for Perivascular Macrophages in Immune-to-
15 Brain Signaling. *Neuron* 2010;65:94–106.

16 74 Williams K, Alvarez X, Lackner AA: Central nervous system perivascular
17 cells are immunoregulatory cells that connect the CNS with the peripheral
18 immune system. *Glia* 2001 [cited 2018 Mar 23];36:156–64.

19 75 He H, Mack JJ, Güç E, Warren CM, Squadrito ML, Kilarski WW, et al.:
20 Perivascular Macrophages Limit Permeability Highlights. *Arterioscler*
21 *Thromb Vasc Biol* 2016;36:2203–2212.

22 76 Shechter R, London A, Schwartz M: Orchestrated leukocyte recruitment
23 to immune-privileged sites: absolute barriers versus educational gates.
24 *Nat Rev Immunol* 2013;13:206–218.

- 1 77 Quintana E, Fernández A, Velasco P, de Andrés B, Liste I, Sancho D, et
2 al.: DNGR-1⁺ dendritic cells are located in meningeal membrane and
3 choroid plexus of the noninjured brain. *Glia* 2015;63:2231–2248.
- 4 78 Meeker RB, Williams K, Killebrew DA, Hudson LC: Cell trafficking through
5 the choroid plexus. *Cell Adh Migr* 2012;6:390–6.
- 6 79 Mendez-Gomez HR, Galera-Prat A, Meyers C, Chen W, Carrion-Vazquez
7 M, Muzyczka N: Crossing the Blood-Cerebrospinal Fluid Barrier in the
8 Mouse Choroid Plexus With an Engineered Receptor/Ligand System. *Mol*
9 *Ther* 2015;23:S65.
- 10 80 Kierdorf K, Prinz M, Gomez Perdiguero E: Development and function of
11 tissue resident macrophages in mice. *Semin Immunol* 2015;27:369–378.
- 12 81 Roth TL, Nayak D, Atanasijevic T, Koretsky AP, Latour LL, McGavern DB:
13 Transcranial amelioration of inflammation and cell death after brain injury.
14 *Nature* 2014;505:223–228.
- 15 82 Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD, et al.:
16 CCR2+Ly-6Chi monocytes are crucial for the effector phase of
17 autoimmunity in the central nervous system. *Brain* 2009;132:2487–2500.
- 18 83 Dong H, Zhang X, Qian Y: Mast cells and neuroinflammation. *Med Sci*
19 *Monit Basic Res* 2014;20:200–6.
- 20 84 Prinz M, Priller J: The role of peripheral immune cells in the CNS in
21 steady state and disease. *Nat Neurosci* 2017;20:136–144.
- 22 85 Nau R, Zettl U, Gerber J, Trostorf F, Michel U, Böttcher T, et al.:
23 Granulocytes in the subarachnoid space of humans and rabbits with
24 bacterial meningitis undergo apoptosis and are eliminated by

- 1 macrophages. *Acta Neuropathol* 1998;96:472–480.
- 2 86 McMenamin PG, Wealthall RJ, Deverall M, Cooper SJ, Griffin B:
3 Macrophages and dendritic cells in the rat meninges and choroid plexus:
4 three-dimensional localisation by environmental scanning electron
5 microscopy and confocal microscopy. *Cell Tissue Res* 2003;313:259–
6 269.
- 7 87 Chinnery HR, Ruitenber MJ, McMenamin PG: Novel Characterization of
8 Monocyte-Derived Cell Populations in the Meninges and Choroid Plexus
9 and Their Rates of Replenishment in Bone Marrow Chimeric Mice. *J*
10 *Neuropathol Exp Neurol* 2010;69:896–909.
- 11 88 Anandasabapathy N, Victora GD, Meredith M, Feder R, Dong B, Kluger
12 C, et al.: Flt3L controls the development of radiosensitive dendritic cells in
13 the meninges and choroid plexus of the steady-state mouse brain. *J Exp*
14 *Med* 2011;208:1695–1705.
- 15 89 Prendergast CT, Anderton SM: Immune cell entry to central nervous
16 system--current understanding and prospective therapeutic targets.
17 *Endocr Metab Immune Disord Drug Targets* 2009 [cited 2018 Mar
18 23];9:315–27.
- 19 90 Fabis MJ, Phares TW, Kean RB, Koprowski H, Hooper DC: Blood– brain
20 barrier changes and cell invasion differ between therapeutic immune
21 clearance of neurotrophic virus and CNS autoimmunity. *PNAS* 2008 [cited
22 2018 Mar 23]; Available from:
23 <http://www.pnas.org/content/pnas/105/40/15511.full.pdf>
- 24 91 Arima Y, Kamimura D, Sabharwal L, Yamada M, Bando H, Ogura H, et

- 1 al.: Regulation of immune cell infiltration into the CNS by regional neural
2 inputs explained by the gate theory. *Mediators Inflamm*
3 2013;2013:898165.
- 4 92 Dendrou CA, Fugger L, Friese MA: Immunopathology of multiple
5 sclerosis. *Nat Rev Immunol* 2015;15:545–558.
- 6 93 da Fonseca ACC, Matias D, Garcia C, Amaral R, Geraldo LH, Freitas C,
7 et al.: The impact of microglial activation on blood-brain barrier in brain
8 diseases. *Front Cell Neurosci* 2014;8:362.
- 9 94 Phares TW, Kean RB, Mikheeva T, Hooper DC: Regional Differences in
10 Blood-Brain Barrier Permeability Changes and Inflammation in the
11 Apathogenic Clearance of Virus from the Central Nervous System. *J*
12 *Immunol* 2006;114:1761–5.
- 13 95 Bilbo SD, Block CL, Bolton JL, Hanamsagar R, Tran PK: Beyond infection
14 - Maternal immune activation by environmental factors, microglial
15 development, and relevance for autism spectrum disorders. *Exp Neurol*
16 2018;299:241–251.
- 17 96 Ashwood P, Wills S, Van de Water J: The immune response in autism: a
18 new frontier for autism research. *J Leukoc Biol* 2006;80:1–15.
- 19 97 Turner MD, Nedjai B, Hurst T, Pennington DJ: Cytokines and
20 chemokines: At the crossroads of cell signalling and inflammatory
21 disease. *Biochim Biophys Acta* 2014;1843:2563–2582.
- 22 98 Masi A, Glozier N, Dale R, Guastella AJ: The Immune System, Cytokines,
23 and Biomarkers in Autism Spectrum Disorder. *Neurosci Bull*
24 2017;33:194–204.

- 1 99 Ramesh G, MacLean AG, Philipp MT: Cytokines and chemokines at the
2 crossroads of neuroinflammation, neurodegeneration, and neuropathic
3 pain. *Mediators Inflamm* 2013;2013:480739.
- 4 100 Biber K, Vinet J, Boddeke HWGM: Neuron-microglia signaling:
5 Chemokines as versatile messengers. *J Neuroimmunol* 2008;198:69–74.
- 6 101 Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Mélik
7 Parsadaniantz S: Current status of chemokines in the adult CNS. *Prog*
8 *Neurobiol* 2013;104:67–92.
- 9 102 Charles A Janeway J, Travers P, Walport M, Shlomchik MJ:
10 *Immunobiology: The Immune System in Health and Disease*. Garland
11 Science, 2001, [cited 2018 Mar 18]. Available from:
12 <https://www.ncbi.nlm.nih.gov/books/NBK27092/>
- 13 103 Metz DP, Bottomly K: Function and regulation of memory CD4 T cells.
14 *Immunol Res* 1999;19:127–141.
- 15 104 Amedei A, Prisco D, D'Elia M: Multiple Sclerosis: The Role of Cytokines
16 in Pathogenesis and in Therapies. *Int J Mol Sci* 2012;13:13438–13460.
- 17 105 Vijayakumar NT, Judy M V.: Autism spectrum disorders: Integration of the
18 genome, transcriptome and the environment. *J Neurol Sci* 2016; DOI:
19 10.1016/j.jns.2016.03.026
- 20 106 Erta M, Giralt M, Esposito FL, Fernandez-Gayol O, Hidalgo J: Astrocytic
21 IL-6 mediates locomotor activity, exploration, anxiety, learning and social
22 behavior. *Horm Behav* 2015;73:64–74.
- 23 107 Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, et
24 al.: Brain IL-6 elevation causes neuronal circuitry imbalances and

- 1 mediates autism-like behaviors. *Biochim Biophys Acta - Mol Basis Dis*
2 2012;1822:831–842.
- 3 108 Bluthé RM, Michaud B, Poli V, Dantzer R: Role of IL-6 in cytokine-induced
4 sickness behavior: a study with IL-6 deficient mice. *Physiol Behav* 2000
5 [cited 2018 Mar 19];70:367–73.
- 6 109 Lucchina L, Depino AM: Altered Peripheral and Central Inflammatory
7 Responses in a Mouse Model of Autism. *Autism Res* 2013;7:273–289.
- 8 110 Gottfried C, Bambini-Junior V, Francis F, Riesgo R, Savino W: The
9 Impact of Neuroimmune Alterations in Autism Spectrum Disorder. *Front*
10 *psychiatry* 2015;6:121.
- 11 111 Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S:
12 Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and
13 Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.
14 *Mediators Inflamm* 2017;2017:1852517.
- 15 112 Dinarello CA: Immunological and Inflammatory Functions of the
16 Interleukin-1 Family. *Annu Rev Immunol* 2009;27:519–550.
- 17 113 Gray SM, Bloch MH: Systematic review of proinflammatory cytokines in
18 obsessive-compulsive disorder. *Curr Psychiatry Rep* 2012;14:220–8.
- 19 114 Manzardo AM, Henkhaus R, Dhillon S, Butler MG: Plasma cytokine levels
20 in children with autistic disorder and unrelated siblings. *Int J Dev Neurosci*
21 2012;30:121–127.
- 22 115 Suzuki K, Matsuzaki H, Iwata K, Kamenno Y, Shimmura C, Kawai S, et al.:
23 Plasma cytokine profiles in subjects with high-functioning autism
24 spectrum disorders. *PLoS One* 2011;6:1–6.

- 1 116 Emanuele E, Orsi P, Boso M, Brogna D, Brondino N, Barale F, et al.: Low-
2 grade endotoxemia in patients with severe autism. *Neurosci Lett*
3 2010;471:162–165.
- 4 117 Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, et al.:
5 Altered cytokine and BDNF levels in autism spectrum disorder. *Neurotox*
6 *Res* 2013;24:491–501.
- 7 118 Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential
8 monocyte responses to TLR ligands in children with autism spectrum
9 disorders. *Brain Behav Immun* 2010;24:64–71.
- 10 119 Jyonouchi H, Sun S, Le H: Proinflammatory and regulatory cytokine
11 production associated with innate and adaptive immune responses in
12 children with autism spectrum disorders and developmental regression. *J*
13 *Neuroimmunol* 2001;120:170–179.
- 14 120 Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de
15 Water J: Elevated plasma cytokines in autism spectrum disorders provide
16 evidence of immune dysfunction and are associated with impaired
17 behavioral outcome. *Brain Behav Immun* 2011;25:40–45.
- 18 121 Abdallah MW, Larsen N, Mortensen EL, Atladóttir HÓ, Nørgaard-
19 Pedersen B, Bonefeld-Jørgensen EC, et al.: Neonatal levels of cytokines
20 and risk of autism spectrum disorders: An exploratory register-based
21 historic birth cohort study utilizing the Danish Newborn Screening
22 Biobank. *J Neuroimmunol* 2012;252:75–82.
- 23 122 Theije CGM, Wu J, Koelink PJ, Korte-Bouws GAH, Borre Y, Kas MJH, et
24 al.: Autistic-like behavioural and neurochemical changes in a mouse

- 1 model of food allergy. *Behav Brain Res* 2014;261:265–274.
- 2 123 Wu H, Wang X, Gao J, Liang S, Hao Y, Sun C, et al.: Fingolimod
3 (FTY720) attenuates social deficits, learning and memory impairments,
4 neuronal loss and neuroinflammation in the rat model of autism. *Life Sci*
5 2017;173:43–54.
- 6 124 Hegazy HG, Ali EHA, Elgoly AHM: Interplay between pro-inflammatory
7 cytokines and brain oxidative stress biomarkers: Evidence of parallels
8 between butyl paraben intoxication and the valproic acid brain
9 physiopathology in autism rat model. *Cytokine* 2015;71:173–180.
- 10 125 Kelly E, Won A, Refaeli Y, Van Parijs L: IL-2 and related cytokines can
11 promote T cell survival by activating AKT. *J Immunol* 2002 [cited 2018
12 Mar 20];168:597–603.
- 13 126 Malek TR: The main function of IL-2 is to promote the development of T
14 regulatory cells. *J Leukoc Biol* 2003;74:961–965.
- 15 127 Fukuda T, Fukushima Y, Numao T, Ando N, Arima M, Nakajima H, et al.:
16 Role of interleukin-4 and vascular cell adhesion molecule-1 in selective
17 eosinophil migration into the airways in allergic asthma. *Am J Respir Cell*
18 *Mol Biol* 1996;14:84–94.
- 19 128 Abdallah MW, Larsen N, Grove J, Rgaard-pedersen BNØ, Thorsen P,
20 Mortensen EL, et al.: Amniotic fluid inflammatory cytokines : Potential
21 markers of immunologic dysfunction in autism spectrum disorders. *World*
22 *J Biol Psychiatry* 2013;528–538.
- 23 129 Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW: Th2
24 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic

- 1 disease. *Respir Res* 2001;2:71–9.
- 2 130 Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH: Maternal Immune
3 Activation Alters Fetal Brain Development through Interleukin-6. *J*
4 *Neurosci* 2007 [cited 2018 May 3]; Available from:
5 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387067/pdf/nihms42804.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387067/pdf/nihms42804.pdf)
6 pdf
- 7 131 Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, et al.: IL-6 is
8 increased in the cerebellum of autistic brain and alters neural cell
9 adhesion, migration and synaptic formation. *J Neuroinflammation*
10 2011;8:1–10.
- 11 132 Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al.: Elevated
12 immune response in the brain of autistic patients. *J Neuroimmunol*
13 2009;207:111–116.
- 14 133 Bickel M: The role of interleukin-8 in inflammation and mechanisms of
15 regulation. *J Periodontol* 1993 [cited 2018 Mar 20];64:456–60.
- 16 134 Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA:
17 Neuroglial activation and neuroinflammation in the brain of patients with
18 autism. *Ann Neurol* 2005;57:67–81.
- 19 135 Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, et al.: Regulation of IL-10
20 and IL-12 production and function in macrophages and dendritic cells.
21 *F1000Research* 2015;4. DOI: 10.12688/f1000research.7010.1
- 22 136 Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A: The IL-12 family of
23 cytokines in infection, inflammation and autoimmune disorders. *Inflamm*
24 *Allergy Drug Targets* 2009 [cited 2018 Mar 20];8:40–52.

- 1 137 Bao K, Reinhardt RL: The differential expression of IL-4 and IL-13 and its
2 impact on type-2 immunity. *Cytokine* 2015;75:25–37.
- 3 138 Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T: The Role of IL-17 and
4 Related Cytokines in Inflammatory Autoimmune Diseases. *Mediators
5 Inflamm* 2017;2017:1–11.
- 6 139 ZHONG F, CUI D, TAO H, DU H, XING C: IL-17A-producing T cells and
7 associated cytokines are involved in the progression of gastric cancer.
8 *Oncol Rep* 2015;34:2365–2374.
- 9 140 Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim S V, et al.: The maternal
10 interleukin-17a pathway in mice promotes autism-like phenotypes in
11 offspring. *Science* 2016;351:933–9.
- 12 141 AL-Ayadhi LY, Mostafa GA: Elevated serum levels of interleukin-17A in
13 children with autism. *J Neuroinflammation* 2012;9:595.
- 14 142 Toussirot E: The IL23/Th17 pathway as a therapeutic target in chronic
15 inflammatory diseases. *Inflamm Allergy Drug Targets* 2012 [cited 2018
16 Mar 20];11:159–68.
- 17 143 Fischer K, Przepiera-Będzak H, Sawicki M, Walecka A, Brzosko I,
18 Brzosko M: Serum Interleukin-23 in Polish Patients with Systemic Lupus
19 Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral
20 Vascular Disease. *Mediators Inflamm* 2017; DOI: 10.1155/2017/9401432
- 21 144 Ziblat A, Nuñez SY, Raffo Iraolagoitia XL, Spallanzani RG, Torres NI,
22 Sierra JM, et al.: Interleukin (IL)-23 Stimulates IFN- γ Secretion by
23 CD56bright Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells
24 Activation. *Front Immunol* 2018;8:1959.

- 1 145 Jyonouchi H, Sun S, Itokazu N: Innate immunity associated with
2 inflammatory responses and cytokine production against common dietary
3 proteins in patients with autism spectrum disorder. *Neuropsychobiology*
4 2002;46:76–84.
- 5 146 Mah AY, Cooper MA: Metabolic Regulation of Natural Killer Cell IFN- γ
6 Production. *Crit Rev Immunol* 2016;36:131–147.
- 7 147 Tostes MHFS, Teixeira HC, Gattaz WF, Brandão MAF, Raposo NRB:
8 Altered neurotrophin, neuropeptide, cytokines and nitric oxide levels in
9 autism. *Pharmacopsychiatry* 2012;45:241–243.
- 10 148 Gutiérrez IL, González-Prieto M, García-Bueno B, Caso JR, Feinstein DL,
11 Madrigal JLM: CCL2 Induces the Production of β 2 Adrenergic Receptors
12 and Modifies Astrocytic Responses to Noradrenaline. *Mol Neurobiol*
13 2018;1–14.
- 14 149 Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de
15 Water J: Associations of impaired behaviors with elevated plasma
16 chemokines in autism spectrum disorders. *J Neuroimmunol* 2011; DOI:
17 10.1016/j.jneuroim.2010.10.025
- 18 150 Fichna M, Żurawek M, Budny B, Komarowska H, Niechciał E, Fichna P, et
19 al.: Elevated serum RANTES chemokine in autoimmune Addison's
20 disease. *Polish Arch Intern Med* 2018; DOI: 10.20452/pamw.4221
- 21 151 Cheng SS, Lukacs NW, Kunkel SL: Eotaxin/CCL11 suppresses IL-
22 8/CXCL8 secretion from human dermal microvascular endothelial cells. *J*
23 *Immunol* 2002 [cited 2018 Mar 20];168:2887–94.
- 24 152 Ahmad SF, Zoheir KMA, Ansari MA, Nadeem A, Bakheet SA, AL-Ayadhi

- 1 LY, et al.: Dysregulation of Th1, Th2, Th17, and T regulatory cell-related
2 transcription factor signaling in children with autism. *Mol Neurobiol*
3 2017;54:4390–4400.
- 4 153 Ashwood P, Anthony A, Torrente F, Wakefield AJ: Spontaneous mucosal
5 lymphocyte cytokine profiles in children with autism and gastrointestinal
6 symptoms: Mucosal immune activation and reduced counter regulatory
7 interleukin-10. *J Clin Immunol* 2004;24:664–673.
- 8 154 Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential
9 monocyte responses to TLR ligands in children with autism spectrum
10 disorders. *Brain Behav Immun* 2010;24:64–71.
- 11

Table 1. Main cytokines with altered levels in autism subjects

DSM	Severity	Described comorbidities	Age (years)	Source	Outcome	Analysis method	Reference
ASD	ND	ND	neonatal	amniotic fluid	↑ MCP-1, IL-4, IL-10, TNF- α and TNF- β	Flow cytometry	[128]
ASD	ND	ND	neonatal	n-DBSS	↓ IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, GM-CSF, IFN- γ ↑ sIL-6R α , IL-8	Flow cytometry	[121]
ASD (DSM-IV)	Mild, moderate and Severe	ND	2-21	Serum	↑ IL-1, IL-6, IL-12, IL-23, TNF- α	ELISA	[117]
ASD (DSM-5)	ND	ND	3-11	PBMCs	↓ CD4+, FOXP3+, T cells ↓ mRNA and protein expression FoxP3 ↑ Tbet, ↑ STAT3, ↑ GATA3	Flow cytometry, PCR and Western Blotting	[152]
ASD (DSM-5)	ND	ND	3-11	PBMCs	↑ ROR- γ t in CD4	PCR and Western Blotting	[152]
ASD (DSM-IIIIR/DSM-IV)	ND	GI issues	2-16	Duodenal Lamina Propria	↑ CD3+/TNF α + ↓ CD3+/IL-10+	Flow cytometry	[153]
ASD (DSM-IIIIR/DSM-IV)	ND	GI issues	2-16	Epithelium	↑ CD3+/TNF α + ↓ CD3+/IL-10+	Flow cytometry	[153]
ASD (DSM-IV)	ND	ND	1-17	PBMCs	↑ TNF- α	ELISA	[145]
ASD (DSM-IV)	ND	GI issues	4-15	PBMCs	↑ TNF- α , IFN- γ ↓ IL-10	Flow cytometry	[96]
ASD (DSM-IV)	Severe (nonverbal adult patients)	ND	18-44	Serum	↑ IL-1 β , IL-6	ELISA	[116]

ASD (DSM-IV)	ND	ND	2.9-4.3	PBMCs	↑ IL-1β, IL-6, IL-8, IL-12 p40	Multiplexing bead immunoassays	[120]
ASD (DSM-IV)	ND	ND	2-14	PBMCs	↑ TNF-α, TNFRI, TNFRII, IL-6, IL-1β	ELISA	[119]
ASD (DSM-IV)	ND	ND	2.2-5	PBMCs	↑ IL-1β, IL-6, TNF-α	Flow cytometry	[154]
ASD (DSM-IV)	ND	ND	5-44	<i>post mortem</i> brain tissue	↑ IL-6, IL10, TGFβ1 (anterior cingulate gyrus)	Human cytokine array kits	[7]
ASD (DSM-IV)	ND	ND	5-44	CSF	↑ IFNγ, TGFβ2, IL-8, MCP1	Human cytokine array kits	[7]
ASD (DSM-IV)	ND	ND	4-37	<i>post mortem</i> brain tissue	↑ IFNγ, IL-6, IL-8, TNF-α (frontal cortex)	Multiplex Bead Immunoassays	[132]
ASD (DSM-IV)	ND	ND	4-14	<i>post mortem</i> brain tissue	↑ IL-6 (cerebellum)	Immunohistochemistry	[131]
ASD (DSM-IV)	ND	ND	7-15	Plasma	↑ IL-1β, IL-1RA, IL-5, IL-8, IL-12 (p70), IL-13, IL-17	ELISA	[115]
ASD (DSM-IV)	ND	ND	3-4.5	Plasma	↑ MCP-1, RANTES, Eotaxin	Multiplexing bead immunoassays	[149]
ASD (DSM-IV)	ND	ND	4.7-10.1	Plasma	↑ IFN-γ	ELISA	[147]
ASD (DSM-IV)	Mild to moderate and Severe	ND	6-11	Serum	↑ IL-17A (proportional increase to severity of autism)	ELISA	[141]
ASD (DSM-IV)	ND	ND	5-10	Plasma	↑ IL-1a ↓ IL-6, G-CSF, EGF	ELISA	[114]

DSM: Diagnostic and Statistical Manual of Mental Disorders; **CSF:** cerebrospinal fluid; **ELISA:** enzyme-linked immunosorbent assay; **IFN:** interferon; **IL:** interleukin; **ND:** not described; **n-DBSS:** neonatal dried blood samples; **PBMC:** peripheral blood mononuclear cells; **PCR:** polymerase chain reaction; **TNF:** tumor necrosis factor.

Table 2. Main cytokines with altered levels in the valproic acid animal model of autism

Animal	Dosage	Embryonic day	Administration via	Source	Age	Outcome	Analysis method	References
BALB/c	600 mg/Kg	E11	Subcutaneous	Dorsal hippocampus	P28	↑ IL-1 β	PCR	[122]
BALB/c	400 mg/Kg and 600 mg/Kg	E12.5	Subcutaneous	Spleen	8-10 weeks	Only VPA did not onset inflammatory response, but showed exacerbated response to a LPS challenge: ↑ IL-1 β , IL-6 and TNF- α expression	PCR	[109]
BALB/c	400 mg/Kg and 600 mg/Kg	E12.5	Subcutaneous	Hippocampus/ Cerebellum	8-10 weeks	↑ IL-6 and TNF- α expression in VPA animals exposed to a LPS challenge	PCR	[109]
Wistar	600 mg/Kg	E12.5	Intraperitoneal	Hippocampus	P40	↑ IL-6, ↑ IL-1 β	ELISA	[123]
Wistar	800 mg/Kg	E12.5	Gavage	Whole brain	P21	↑ IL-1 β , IL-6, TNF- α	ELISA	[124]

IL: interleukin; **PCR:** polymerase chain reaction.

Legend of figures

Figure 1. Th1, Th2, Th17 commitment lineage from naïve CD4+ T cells. The main functions of each immune response and the signature cytokine are highlighted in the boxes. APC: antigen-presenting cell; NK: natural killer cell; T-bet: T box expressed in T cells; GATA: GATA-binding protein; ROR: Retinoid-related orphan receptor; IL: Interleukin; IFN: Interferon; TGF: Transforming growth factor.

Figure 2. Main results of cytokines altered both in ASD subjects and in VPA animal model. At the interface of the columns and rows are shown the common findings both to humans and to animal model in different biological sources. The references are already cited in Table 1.




Figure 1. Th1, Th2, Th17 commitment lineage from naïve CD4+ T cells.




Figure 2. Main results of cytokines altered both in ASD subjects and in VPA animal model.